Year: 2020
Type: reference-entry
Abstract: A lthough surgical resection is curative inmost patientswith basal cell carcinoma (BCC), recurrent ormore ad-vanced disease may be treated with a combination of surgery and radiation.1 Cisplatin is sometimes used for pa-tients withmetastatic BCC,2 but no systemic therapy was ap-proved for the treatment of BCC until recently with the ad-vent of vismodegib. Response rates to systemic vismodegib were 30%and43%forpatientswithmetastatic and locally ad-vanced BCC, respectively, with a median duration of re-sponse of 7.6 months.3 As vismodegib becomes increasingly used, it will be im-portant to address how to best integrate this new agent into existing therapy for advanced BCC. Improved understanding of how vismodegib interacts with radiation in this disease would help determine the optimal timing and sequencing of these various treatment modalities to enhance response rate and progression-free survival. Only one case of radiotherapy with vismodegib has previously been reported for the treat-ment of squamous cell carcinoma.4 We report the treatment of2casesof recurrentheadandneckBCCusing thisnovel com-bination of vismodegib and concurrent radiotherapy. Report of Cases With institutional review board approval of Stanford Univer-sity, a search of patients who received vismodegib and con-current radiotherapywas conducted. Twopatientswere iden-tifiedashavingbeen treatedwithvisomodegibandconcurrent
Source: Definitions
DOI: 10.32388/erjxiq
Author: National Cancer Institute
Language: English
Subfield: Dermatology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
OpenAlex ID: W4246883504
